Large company small molecule share of Phase I clinical trial starts vs Antibody-drug conjugate trial starts
In 2025, large company small molecule share of Phase I clinical trial starts worldwide was 66%; antibody-drug conjugate trial starts was 349.
Change the pair
Compare different indicators
The series
Over time
Global, annual figures, spaced by time from 2022 to 2025 . Different units, drawn on separate scales and clipped to the years both series publish; earlier history stays on each indicator’s own page. Read the values, not the heights.
Large company small molecule share of Phase I clinical trial starts
Unit: % · 2 observations
Antibody-drug conjugate trial starts
Unit: count · 4 observations
Shared periods
Side by side
2 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.
Provenance
Where these numbers come from
Large company small molecule share of Phase I clinical trial starts
Percentage of Phase I clinical trial starts sponsored by large pharmaceutical companies that investigate small molecule drugs.
2 observations charted in Global · source organisations: IQVIA
Antibody-drug conjugate trial starts
Count of interventional studies whose record mentions an antibody-drug conjugate by class or by payload/brand stem (deruxtecan, vedotin, govitecan, emtansine, tirumotecan, rezetecan and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
4 observations charted in Global (of 6 annual records) · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring